

**ENDOBROCHIAL ULTRASONOGRAHY FOR LUNG  
CANCER STAGING IN NEGATIVE MEDIASTINUM ON  
COMPUTED TOMOGRAPHY**

*Thesis*

Submitted for partial fulfillment of M.Sc. degree in  
**Chest disease and tuberculosis**

Presented by

**Mahmoud Mohamad Alfeky**

**M.B.Bch.**

**Supervised by:**

**prof.Dr.**

**NARIMAN ABDEL RAHMAN HELMY**

**Professor of chest disease**

**Chest department,**

**Faculty of Medicine, Cairo University**

**Dr.**

**Naglaa Bakry Ahmad**

**Lecturer of chest disease**

**Chest department,**

**Faculty of Medicine, Cairo University**

**Chest Department,**

**Faculty of Medicine, Cairo University**

*2009*

## Acknowledgement

Before and above all, all thanks to “**ALLAH**” who makes every thing and supports any one return to hem.

I wish to express my deepest gratitude to Prof. **Nariman Abdel Rahman Helmy**, Professor of Chest Diseases, faculty of Medicine, Cairo University, for her support, sincere guidance, kind supervision, and continuous encouragement and advices to me through the whole work.

My sincere gratitude and appreciation to Dr. **Khaled Mahmoud Kamel**, Assistant Professor of Chest Disease, faculty of Medicine, Cairo University. I’m truly thankful for his time and support and I cannot deny gaining my benefit from his great experience in bronchoscopy and endobronchial ultrasonography.

I am very grateful to Dr. **Naglaa Bakry Ahmed**, Lecturer of Chest Disease, faculty of Medicine, Cairo University, for her constant assistance and valuable support.

Lastly I wish to express my great thanks to my **mother** for her support and always being my backbone.

# **ABSTRACT**

Lung cancer is the leading cause of death from malignancy world wide.

The TNM (T = primary tumor, N = regional lymph nodes, M = distant metastasis) staging system for this type of cancer subdivides patients into anatomic groups. This system is central to determining treatment options and prognosis and to comparing survival among therapeutic trials. In the absence of distant metastasis, mediastinal lymph node metastasis in non-small-cell lung cancer is a critical issue. Almost half of patients with this type of cancer present with metastasis to the mediastinal lymph nodes, a characteristic that is the major obstacle to cure.

To evaluate the mediastinal lymph nodes, computed tomography of the thorax with intravenous contrast scanning should be done in patients suspected of having lung cancer. The diagnostic accuracy of computed tomography for detecting lymph node metastasis in lung cancer is about 60% in non-small-cell lung cancer, the risk for metastasis to the mediastinal lymph nodes increases with lymph node size.

## **Key Words:**

**Lung Cancer, lung cancer Staging, Endobronchial ultrasonography**

# CONTENTS

	Page
<b>CONTENTS</b> .....	<b>i</b>
➤ <b>LIST OF ABBREVIATIONS</b> .....	<b>ii</b>
➤ <b>LIST OF TABLES</b> .....	<b>v</b>
➤ <b>LIST OF FIGURES</b> .....	<b>iv</b>
<b>INTRODUCTION</b> .....	<b>1</b>
<b>AIM OF THE WORK</b> .....	<b>3</b>
<b>REVIEW OF LITERATURE</b>	
• <b>Lung Cancer</b> .....	<b>4</b>
• <b>lung cancer Staging</b> .....	<b>35</b>
• <b>Endobronchial ultrasonography</b> .....	<b>61</b>
<b>SUBJECTS &amp; METHODS</b> .....	<b>87</b>
<b>RESULTS</b> .....	<b>94</b>
<b>CASE PRESENTATION</b> .....	<b>102</b>
<b>DISCUSSION</b> .....	<b>128</b>
<b>SUMMARY</b> .....	<b>138</b>
<b>CONCLUSION &amp; RECOMMENDATIONS</b> .....	<b>140</b>
<b>REFERENCES</b> .....	<b>142</b>
<b>APPENDIX</b> .....	<b>155</b>
<b>ARABIC SUMMARY</b>	

## List of Abbreviations

ACTH	:	Adrenocorticotrophic hormone
BAL	:	Bronchoalveolar Lavage
CP	:	convex probe
CT	:	Computed tomography
EBUS	:	Endobronchial ultrasound
EBUS-TBNA	:	Endobronchial ultrasonography-Trans bronchial needle aspiration
EP	:	echo probes
FDG	:	Fluorodeoxyglucose
FNA	:	Fine needle aspiration
FOB	:	Fiberoptic bronchoscopy
H&E	:	Hematoxylin and eosin
HRCT	:	High resolution Computerized tomography
Hz	:	Hertz
IASLC	:	International Association for the Study of Lung Cancer
KHz	:	Kilo hertz
LN	:	Lymph node
Lt	:	Left
MHz	:	Mega hertz
MRI	:	Magnetic resonance imaging
NSCLC	:	Non small cell lung cancer
P-A	:	Postero-Anterior
P.A	:	pulmonary artery
PET	:	Positron emission tomography
Rt	:	Right
SCLC	:	Small cell lung cancer
SIADH	:	syndrome of inappropriate secretion of antidiuretic hormone
SVC	:	Superior Vena Cava
TBLB	:	Transbronchial lung biopsy
TBNA	:	Transbronchial needle aspiration
TNM	:	Tumor, Node, Metastasis
TTNA	:	Transthoracic needle aspiration
UT	:	Ultrasonic Testing
VATS	:	Video-assisted thoracoscopic surgery
Vs.	:	Versus
W H O	:	World Health Organization

# List of tables

	Page
Table (1):	Extent of Disease at Presentation
Table (2):	Illustrates Lymph nodes of the lung, its location, afferent, efferent, and regions of drainage
Table (3):	TNM classification
Table (4):	TNM Subsets by Stage
Table (5):	Bronchoscopic detection of mediastinal and hilar lymph nodes
Table (6):	Comparison between different invasive staging modalities.
Table (7):	Sex distribution in studied patients
Table (8):	Mean, standard deviation (SD), minimum and maximum values of age
Table (9):	Descriptive table shows frequency and percentages of presenting symptoms in studied patients
Table (10):	Descriptive table shows frequency and percentages of lesion site
Table (11):	Descriptive table shows frequency and percentages of diagnostic methods
Table (12):	Descriptive table shows frequency and percentages of histopathological types
Table (13):	Descriptive table shows frequency and percentages of L.N. detected by EBUS and results of TBNA

## List of figures

	Page
Fig. (1): Age Specific Incidence Rates of NHL per 100,000 population for each Sex Egypt, Gharbiah 2000-2002.....	46
Fig. (1): Computed tomography scan of enhancing cerebral metastasis with marked oedema and mass effect	
Fig. (2): Massive left adrenal (open arrow) and hepatic metastases	
Fig. (3): Transverse CT image with a central tumor in the left upper lobe and atelectasis (T3 tumor)	
Fig. (4): Transverse CT image in with squamous cell carcinoma of the left lower lobe shows large left lower lobe mass	
Figure(5): Autofluorescence bronchoscopy and white light bronchoscopy demonstrating mucosal lesion	
Fig. (6): Nodal chart.	
Fig. (7): Schema of Mountain and Dresler classification system,	
Fig. (8): (Regional lymph node classification for lung cancer staging.).	
Fig. (9): CT showing enlarged right paratracheal lymph node in a 65-year-old patient with a primary lung cancer of the right middle lobe	
Fig. (10): CT of the mediastinum with adenocarcinoma of the right upper lobe showing an enlarged pretracheal lymph node	
Fig. (11): Adenocarcinoma of the right upper and middle lobes in. CT scan obtained at the level of the aortopulmonary window shows enhancing low right paratracheal nodes	
Fig. (12): Illustration of a vibrating tuning fork producing a sequence of compressions and rarefactions in the surrounding air, producing soundwaves	
Fig. (13): Diagram shows an ultrasound pulse that was generated by a transducer and consists of two wave cycles	
Fig. (14): The reflection of an ultrasound pulse emitted from the probe.	
Fig. (15): The reflected signals displayed as, A-mode (Amplitude) shows the depth and the reflected energy from each scatterer. B-mode (Brightness) shows the energy as the brightness of the point. The motion is seen as a curve (and horizontal lines for the non moving scatterers) in a M-mode plot (Motion)	
Fig. (16): Plain endobronchial ultrasound probe	
Fig. (17): Endobronchial ultrasound probe inside the balloon catheter.	

- Fig. (18): Left: The RP is placed through the working channel of a standard bronchoscope
- Fig. (19): Linear EBUS has the ultrasound transducer incorporated at the distal end of the bronchoscope
- Fig. (20) : Endobronchial ultrasound - basic anatomy
- Fig. (21): A 360° cross-sectional EBUS image showing enlarged LN.
- Fig. (22): EBUS shows enlarged LN with intact pulmonary artery
- Fig. (23): Lymph node 11 superior (11s) swelling < 10 mm in diameter was observed by EBUS, and there was no direct invasion of the pulmonary artery (PA). However, it was unclear on the chest CT scan.
- Fig. (24): Diagram showing the TBNA catheter and EBUS probe are inserted simultaneously through a double-channel bronchoscope.
- Fig. (25): The bronchoscope image shows that the left catheter is the EBUS probe, and the right catheter is the TBNA catheter by which the pretracheal lymph node was penetrated.
- Fig. (26): A; tip of the ultrasonic bronchoscope with the linear curved-array ultrasonic transducer. B; the balloon attached to the tip of the bronchoscope is inflated with normal saline solution
- Fig. (27): (A) CT chest showing enlarged left hilar lymph node. (B) EBUS scan showing lymph node 11 (1.23 x 1.55 cm in diameter) and the pulmonary artery (PA) adjacent to the lymph node. (C) Real-time CP-EBUS-guided TBNA was performed.
- Fig. (27): (A) CT chest showing enlarged pretracheal lymph node. (B) EBUS scan shows lymph node 3, which is clearly distinguishable from the superior vena cava (SVC) by use of the Doppler mode. (C) Real-time CP-EBUS-guided TBNA revealed adenocarcinoma
- Fig. (28): Endobronchial ultrasound Bronchoscope
- Fig. (29): A 360° cross-sectional EBUS image showing enlarged LN
- Fig. (30): EBUS shows enlarged L.N with intact pulmonary artery
- Fig. (31): Percentages of presenting symptom
- Fig. (32): Site of the lesion
- Fig. (33): Method of diagnosis
- Fig. (34): Type of lesion
- Fig. (35): L.N location
- Fig. (36): Chest x ray P.A view of a male patient 62 years old heavy



smoker, showing right middle and lower lung zones semi homogenous opacity with a fuzzy outline extending medially to the mediastinum.

Fig. (37): C.T chest with contrast showed a well defined soft tissue mass is seen in the lower lobe of right lung.

Fig. (38): EBUS by direct technique revealed two small subcarinal lymph nodes (station 7)

Fig. (39): At the ridge between right upper lobe and intermediate bronchus (station 10R) EBUS revealed two small lymph nodes

Fig. (40): Chest X ray P.A view of a male patient 65 years old, heavy smoker, showing left paratracheal mass

Fig. (41): C.T chest with contrast, the apical segment of left lower lobe shows a medial pleural based soft tissue mass.

Fig. (42): EBUS by direct technique revealed two small subcarinal lymph nodes (station 7).

Fig. (43): EBUS at the carina between the left upper and lower bronchi (station 10L) revealed one small lymph node

Fig. (44): C.T chest with contrast of a male patient 60 years old, heavy cigarette smoker showed a well defined soft tissue mass is seen in the right upper lobe.

Fig. (45): EBUS by direct technique revealed subcarinal echogenic shadow of lymph node (station 7).

Fig. (46): chest x ray P.A view of a male patient 60 year's old, heavy smoker, showing left upper lung zone semi homogenous opacity.

Fig. (47): C.T chest with contrast showed a well defined soft tissue mass is seen in the upper lobe of left lung.

Fig. (48): EBUS by direct technique at the ridge between left upper lobe and left lower lobe revealed one lymph node.

Fig. (49): Chest X ray P.A view of a female patient 42 years old, showing large irregular shaped semihomogenous opacity.

Fig. (50): C.T chest with contrast showed a well defined soft tissue mass is seen in the lower lobe of right lung.

Fig. (51): EBUS by direct technique revealed no mediastinal lymphadenopathy

Fig. (52): Chest X ray P.A view of a male patient 64 years old, heavy smoker, showing Semi homogenous opacity occupying the left lower lung zone.

Fig. (53): C.T chest with contrast showed a well defined soft tissue mass is seen in the upper lobe of left lung,

Fig. (54): EBUS by direct technique revealed no mediastinal lymphadenopathy .



## INTRODUCTION

Lung cancer continues to be a major health problem, it is the most common cause of cancer-related deaths in men and women worldwide (*Finkelstein et al., 2003*).

Accurate staging in patients with lung cancer is of paramount importance. It will guide choices of treatment and determine prognosis and outcome (*Edward et al., 1999*).

Computed tomography (CT) scanning is the standard imaging modality widely used to staging, planning treatment, evaluating response, and estimating prognosis of lung cancer (*Kazuya et al., 2000*).

Conventional radiologic tools such as chest CT scan and chest tomography are frequently unreliable in staging mediastinal lymph node metastases of lung cancer, with limited diagnostic accuracy since interpretation relies principally on lesion size (*Oliver et al., 2005*).

Because the mediastinal and hilar lymph nodes are adjacent to the pulmonary artery or vein, and movement and partial volume effects of these vessels occur, it is occasionally difficult to differentiate lymph nodes from vascular structures. Therefore, the diagnosis of lymph node metastasis by CT scan and chest tomography is usually less reliable in the hilum and in the mediastinum. (*Hiroaki et al., 2002*).

The technique of endobronchial ultrasonography (EBUS) has improved significantly in the last years. However, it has been used in very



few studies to determine the mediastinal and hilar lymph node metastases (*Herth et al., 2002*).

EBUS offers a unique way of imaging airway and parabronchial structures during a bronchoscopic procedure. The procedure is safe, minimally invasive and does not require general anesthesia or hospitalization. The complication rate is extremely low (*Koji et al., 2005*).

EBUS may be superior to conventional radiologic tools in detection of mediastinal and hilar lymph node metastases. Clinically, it should be considered in the staging of all patients without mediastinal lymph node enlargement on CT scan. It could be an obvious choice for the primary procedure, to know whether lymph node metastases are present prior to treatment. In order to improve the accuracy of diagnosis of lymph node metastases (*Gerard et al., 2007*)

## AIM OF THE WORK

**T**o evaluate the role of Endobronchial Ultrasonography in staging lung cancer in patient without mediastinal lymph nodes on chest computed tomography.



## **LUNG CANCER**

Lung cancer is one of the most important diseases in respiratory medicine. Worldwide, it is the commonest cancer in men, virtually the commonest in women, and has a greater total incidence than that of colorectal, cervical, and breast cancer combined (*Stephen and Joanna, 2002*).

### **Epidemiology of lung cancer:**

#### **Incidence:**

As detected by age adjusted morality rate, in males it increases steadily then it is plateaued then started to decline, for women the incidence is still increasing world wide. The rate of increase is 0.5% per year. Male/female ratio is 1.4:1 (*Greenlee et al., 2001*).

#### **Mortality rates:**

Lung cancer has a median survival of 6-12 months from the time of diagnosis with an overall 5-year survival of 5-10% (*Stephen and Joanna, 2002*).

Lung cancer is the leading cause of cancer death in the United States, with an annual incidence of 170,000 cases (*Pankaj et al., 2007*).

Lung cancer remains the leading cause of cancer death in both men and women even though an extensive list of risk factors has been well-characterized. Far and away the most important cause of lung cancer is exposure to tobacco smoke through active or passive smoking. The reductions in smoking prevalence in men that occurred in the late 1960s through the 1980s will continue to drive the lung cancer mortality rates



downward in men during the first portion of this century. This favorable trend will not persist unless further reductions in smoking prevalence are achieved (*Anthony et al., 2003*).

The prognosis of lung cancer is poor, with less than 15% of patients surviving 5 years after diagnosis. The poor prognosis is attributable to lack of efficient diagnostic methods for early detection and lack of successful treatment for metastatic disease. Most patients (>75%) present are rarely curable with current therapies. Within the last decade, rapid advances in molecular biology, pathology, bronchology, and radiology have provided a rational basis for improving outcome (*Fred et al., 2001*).

## **Pathology of Lung Cancer:**

The distinction between SCLC and NSCLC is critical, both clinically and in terms of tumor genetics and biology. Small cell lung cancer (SCLC) was first described as a tumor of the bronchus, as opposed to a round cell sarcoma. The World Health Organization (WHO) and International Association for the Study of Lung Cancer (IASLC) have sponsored workshops to develop standardized morphologic classifications of lung cancer and SCLC subtypes. Although the subtypes of SCLC are not clinically useful in determining therapy, the recognition that mixed tumors containing two or more elements of SCLC, adenocarcinoma, or squamous cell carcinoma has promoted the concept that the major forms of lung cancer are closely related, perhaps arising from a common stem cell. Bronchogenic carcinomas are 95% all primary lung tumors. The remaining 5% of primary lung cancers are of other various origins and either benign or malignant. The revised WHO classification of lung cancer included: